{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-041428","form_type":"8-K","ticker":"NAGE","cik":"0001386570","company_name":"Niagen Bioscience, Inc.","filed_at":"2023-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.827223+00:00","generated_at":"2026-06-07T13:23:34.279756+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"ChromaDex extends $10M revolving credit line maturity to Nov 2025; interest rate floor raised to 8.25%","bullets":["Revolving credit line of up to $10M extended to November 12, 2025; no amounts outstanding as of filing.","Interest rate changed to greater of 8.25% or Prime plus 1%; additional 5% during default event.","Amendment requires maintaining at least 75% of consolidated cash at Western Alliance Bank starting Jan 31, 2024.","$50,000 renewal fee paid; share repurchases limited to $2.5M aggregate during the term.","Quick ratio covenant of 1.15:1.00 added to qualify for streamlined reporting period."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-041428","json":"https://secwatch.observer/filing/0001628280-23-041428.json","markdown":"https://secwatch.observer/filing/0001628280-23-041428.md","text":"https://secwatch.observer/filing/0001628280-23-041428.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1386570/000162828023041428/0001628280-23-041428-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1386570/000162828023041428/cdxc-20231208.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T13:23:34.279756+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5f9582dc7840f96f3adbb27f745e451611842070","claim":"Niagen Bioscience, Inc. amended revolving credit of up to $10.0 million with Western Alliance Bank at 8.25% per year maturing November 12, 2025.","evidence_excerpt":"the “Credit Agreement”) dated November 1, 2019 among the Borrowers and Western Alliance Bank (the “Lender”). The Credit Agreement provides for a revolving credit line of up to $10.0 million. The Amendment extended the maturity date of the revolving credit line under the Credit Agreement to November 12, 2025 and also increased the interest rate to be calculated at a","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828023041428/0001628280-23-041428-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"revolving credit"},{"label":"Principal","value":"up to $10.0 million"},{"label":"Counterparty","value":"Western Alliance Bank"},{"label":"Rate","value":"8.25% per year"},{"label":"Maturity","value":"November 12, 2025"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"53b478d76403f7e5d411a3b8f0aa38ef5db975b0","claim":"Niagen Bioscience, Inc. amended Amendment to Business Financing Agreement with Western Alliance Bank valued at Revolving credit line of up to $10.0 million; maturity extended to November 12, 2025; interest rate (effective 2023-12-08).","evidence_excerpt":"On December 8, 2023, ChromaDex Corporation (the “Company”), and the Company’s wholly owned subsidiaries, ChromaDex, Inc., a California corporation, and ChromaDex Analytics, Inc., a Nevada corporation (together with the Company, the “Borrowers”) entered into an amendment (the “Amendment”) to the business financing agreement (as amended, the “Credit Agreement”) dated November 1, 2019 among the Borrowers and Western Alliance Bank (the “Lender”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828023041428/0001628280-23-041428-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Western Alliance Bank"},{"label":"Value","value":"Revolving credit line of up to $10.0 million; maturity extended to November 12, 2025; interest rate"},{"label":"Effective","value":"2023-12-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}